Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.
Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.
New research suggests that an antidepressant medication, repurposed, could target a novel molecular pathway that causes an aggressive form of medulloblastoma.
A blue-ribbon team of national experts stated that professional pessimism and out-of-date myths rather than current science may compromise the care of patients with brain cancer.
A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, according to new research.
New research helps explain why brain tumors occur more often in males and frequently are more harmful than similar tumors in females. For example, glioblastomas, the most common malignant brain tumors, are diagnosed twice as often in males, who suffer greater cognitive impairments than females and do not survive as long.
New research shows the protein neurons use to stay alive and healthy is used by brain cancer cells to maintain longevity to grow and metastasize. The findings could lead to breakthroughs in treatments for brain cancer.
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, according to results of a study.
A blue-ribbon team of national experts on brain cancer said that professional pessimism and out-of-date myths rather than current science may compromise the care of patients with cancer that has metastasized to the brain.
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression—this finding could ultimately lead to new ways to bring about the death of the tumor.
A tool to help brain surgeons test and more precisely remove cancerous tissue was successfully used during surgery, according to a Purdue University and Brigham and Women's Hospital study.
An exciting new study has characterized the cellular diversity in glioblastoma tumors from patients, which may pave the way for the development of new treatments.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
The hormone progesterone could become part of therapy against the most aggressive form of brain cancer.
A synthetic peptide carrier is a potential delivery vehicle for chemotherapy drugs for brain cancer and for other neurologic medications, according to new research.
Researchers have identified a genetic mutation in brain cancer tumor cells that plays a role in both the growth and the death of the cell.
Is there a difference in dosing (1 hour prior to radiotherapy vs bedtime) with temozolomide plus radiotherapy for glioblastoma multiforme?
Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer.
Stem cells derived from human body fat have been successfully used to deliver biologic treatments directly to the brains of mice with the most common and aggressive form of brain tumor, significantly extending their lives.
New mutations in pediatric brain tumors known as high-grade gliomas have been identified, and most often occur in the youngest patients.
The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.
The most common genetic alteration ever reported in the brain tumor ependymoma has been identified. Researchers also have evidence that the alteration drives tumor development.
Patients with malignant astrocytoma whose tumors carry the gene mutation IDH1 may benefit greatly from surgical removal of the largest possible amount of tumor.
First-of-its-kind research shows promise for developing a method to clearly identify cancerous tissue during surgery. These findings may potentially improve outcomes for those undergoing surgery to remove glioblastoma multiforme.
Years can pass between the time a breast cancer patient goes into remission and a related brain tumor develops. During that time, the breast cancer cells somehow escape detection.
A gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.
Researchers have also created an experimental vaccine to attack immune system targets related to cancer stem cells, the cells from which malignant brain tumors are believed to originate and regenerate.
Patients with recurrent GBM treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.
A known genetic pathway is active in many difficult-to-treat pediatric brain tumors known as low-grade gliomas. This finding offers a potential new target for the treatment of these cancers.
A new approach selectively permeabilizes the blood-brain barrier at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic.
Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to 6 months after treatment.
Overall survival was improved for adults age 50 years and younger with brain cancer who were treated with stereotactic radiosurgery that was not combined with whole-brain radiotherapy.
A specific protein has been found in nearly 100% of high-grade meningiomas, which is the most common form of brain tumor. This finding suggests a new target for therapies for a cancer that does not respond to current chemotherapy.
A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy.
Cellular therapy and gene therapy have been successfully combined in a mouse model to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
About 15% of patients with glioblastoma could receive personalized treatment with drugs currently used in other cancers, based on new research that has identified 18 genes responsible for driving glioblastoma multiforme.
A large-scale analysis of the association between DNA viruses and human malignancies suggests that many of the most common cancers are not associated with DNA viruses
When 96 pilocytic astrocytomas were analyzed by whole-genome sequencing, all had MAPK-pathway alterations. This indicates that pilocytic astrocytoma is predominantly a single-pathway disease.
An oncolytic virus infected and killed both brain cancer stem cells and differentiated compartments of the common and deadly malignant brain tumor, glioblastoma multiforme (GBM), when combined with the immunosuppressant drug rapamycin.
An abnormal metabolic pathway drives the growth of cancer cells in a particular glioblastoma subtype, according to new research.
Attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study.
Genetic material secreted by bone marrow cells was used to reduce glioma tumor volume in a recent study.
The imaging technique of DTI allows neurosurgeons to visualize important pathways in the brain. This allows them to better adapt brain tumor surgeries and preserve language, visual function, and motor function while removing cancerous tissue.
Among patients undergoing surgery for a brain tumor, low T3 (triiodothyronine) syndrome has been found to be predictive of unfavorable clinical outcomes and depressive symptoms.
Low levels of the thyroid hormone triiodothyronine (T3) predict unfavorable outcomes after neurosurgery for the treatment of brain tumors.
Adipose tissue may provide a more efficient, less costly, and less invasive source of mesenchymal stem cells (MSCs) than bone marrow.
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Fluorescence form 5-aminolevulinic acid (5-ALA) has been used to guide resection of recurrent GBM. Before surgery, the patient ingests 5-ALA, then the tumor cells fluoresce intraoperatively in response to certain wavelengths of light.
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15% of brain tumors known as meningiomas.
The forecast enables physicians to rapidly identify how well a tumor is responding to a particular therapy and allows a quick pivot to a new therapy in a critical time window if the current therapy is not effective.
ELTD1, a protein linked with angiogenesis, is the strongest candidate for a significant association with glioma out of nearly 200 possible markers.
Researchers have, for the first time, identified a new group of growth factor receptors that signal to brain tumors, which brings treatment of neurofibromatosis type 2 one step closer to a nonsurgical therapeutic option.
Patients with aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.
For patients receiving radiotherapy for glioblastoma, use of clinical target volume margins as small as 5 mm does not lead to an increase in marginal failures.
Imaging with 18F-FLT positron emission tomography provides tumor-specific details accurately and noninvasively in persons with gliomas.
Hemodynamic changes associated with pregnancy explain the growth of benign tumors in pregnant women. The study also identified some key characteristics associated with rapid growth of meningiomas in pregnant women.
A cell growth pathway that is unusually active in pediatric brain tumors known as gliomas has been identified. This same growth pathway was previously identified as a critical contributor to brain tumor formation and growth in neurofibromatosis-1.
Insurance coverage affects in-hospital mortality for brain tumor patients undergoing craniotomy.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Persons with glioblastoma who undergo repeated resections can have improved survival, indicate the findings of a recent study.
A needs assessment tool can identify specific needs of caregivers of patients with a primary malignant brain tumor.
A facility favoring early surgical resection of low-grade glioma had better overall survival rates than did a facility favoring watchful waiting.
Glioblastoma multiforme tumors can originate not only from the glial cells that make up the supportive tissue of the brain and from neural stem cells, but also from other types of differentiated cells in the nervous system, including cortical neurons.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Short-term outcomes no worse with advanced age after craniotomy for malignant brain tumors.
Majority exhibit positive social adjustment over long term; risk factors ID'd for lasting issues.
Long-term follow-up results from two clinical trials have confirmed substantially longer survival for certain patients with anaplastic oligodendrogliomas if they are treated with a combination of chemotherapy and radiation therapy instead of radiation alone.
For children who undergo brain radiation therapy, permanent neurocognitive adverse effects are a significant risk. These risks arise because the radiation often encounters healthy tissue, which reduces the formation of new cells, particularly in the hippocampus.
A controlled fasting period lasting no more than 48 hours improved the effectiveness of chemotherapy and radiation therapy in mice with gliomas.
Persons with more than one glioblastoma tumor upon diagnosis experience significantly worse survival than do patients with a solitary lesion.
Strongest associations seen for oligodendroglial tumors, gliomas with IDH1/IDH2 mutations.
A slower-growing set of glioblastoma multiforme cells appears to be the source of the brain cancer's recurrence following standard drug therapy.
A rare genetic variant has been found to increase a person's risk of developing glioma, but also cuts in half the person's risk of death.
Physicians have changed management recommendations for almost half of patients with known or suspected brain tumors after PET/CT findings.
Dabrafenib, which targets a genetic mutation that is active in half of melanoma cases, substantially and safely shrank metastatic tumors.
Three patients with glioblastoma lived longer than predicted after receiving transplants of their own blood stem cells that had been gene-modified.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
A new transvestibular endoscopic method for removing tumors at the base of skull features shorter operation and recovery periods, fewer complications, and no scars.
A common amino acid may help restore function to cancer-fighting T-cells in persons with glioblastoma, say researchers.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
A large follow-up analysis of the complete Danish Cancer Registry showed no increased risk of tumors of the central nervous system, providing little evidence for a causal association.
The regulatory protein FoxM1 is essential for the continued growth of medulloblastoma and is significantly and negatively correlated with survival, making it a useful prognostic marker.
The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
Epileptic seizures—common among people with primary brain tumors—may be related to the release of excess levels of glutamate, and may be controlled with the drug sulfasalazine.
Patients with glioblastoma—the most common and most malignant form of brain tumor in adults—may live longer if they take valproic acid rather than another type of agent to control seizures.
The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.
Medications were able to block a newly identified cancer-promoting pathway and delay glioma growth in mice, suggesting a new treatment option to combat malignant glioma.
Audiometric testing, awareness of the symptoms, and knowledge of which drugs are ototoxic can help protect young cancer patient's hearing.
Presentations on emerging standards of care in radiotherapy from the Future of Radiation Medicine 2011 symposium are reviewed.
A recent study of patients with recurrent malignant glioma revealed exercise behavior to be a strong independent predictor of survival.
Glioblastoma treatment may be made more effective by introducing a chemotherapy-resistant gene into normal bone marrow stem cells to protect them from the toxic effects of chemotherapy.
People who underwent cancer therapy as children have a heightened risk of developing gastrointestinal (GI) complications later in life, a new study shows.
FOLFIRINOX was more effective than gemcitabine in increasing survival and delaying disease progression in metastatic pancreatic cancer, plus new indications for everolimus and sunitinib.
The FDA has approved a portable therapeutic system that can be used at home by adults who have glioblastoma that has recurred or progressed following chemotherapy and radiotherapy.
Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.
A laboratory version of a drug approved for use in Europe successfully stopped malignant brain-tumor cells from finding the blood vessels they need to thrive.
Only a relatively small proportion of second cancers in adults is related to routine radiotherapy administered for initial disease, according to the findings of a recent study.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|